Literature DB >> 21555993

Multiple sclerosis: Benefits of alemtuzumab in MS.

Heather Wood.   

Abstract

Entities:  

Year:  2011        PMID： 21555993     DOI： 10.1038/nrneurol.2011.57

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  1 in total

1.  Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Authors:  Alasdair J Coles; Edward Fox; Anton Vladic; Suzanne K Gazda; Vesna Brinar; Krzysztof W Selmaj; Ann Doan-Do Bass; Daniel R Wynn; David H Margolin; Stephen L Lake; Susan Moran; Jeffrey Palmer; M Shelton Smith; D Alastair S Compston
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182
  1 in total
  1 in total

1.  Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS.

Authors:  Hongxia Duan; Shu Xing; Yongting Luo; Liqun Feng; Irene Gramaglia; Ying Zhang; Di Lu; Qiqun Zeng; Kelong Fan; Jing Feng; Dongling Yang; Zhihai Qin; Pierre-Olivier Couraud; Ignacio A Romero; Babette Weksler; Xiyun Yan
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.